Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.

Digital delivery of GLP-1RA therapy in women results in a mean weight loss of 16.1 kg, or 15.5% of baseline weight, in a real-world UK cohort.

• Why it matters: Understanding how digital care models perform outside clinical trials is crucial for expanding access to effective obesity treatments, especially among women.
• What they did: An observational study of 8,127 women using tirzepatide through a structured digital program with biochemical monitoring, weekly video follow-up, and dose titration was conducted.
• The result: The program achieved high retention (91.4% at 6 months), significant improvements in biomarkers, and no serious adverse events, supporting the feasibility of large-scale digital obesity pharmacotherapy.